Background: Enterococci frequently cause biofilm infections but susceptibility of clinical isolates growing in biofilms has not been investigated. The minimum biofilm eradicating concentration (MBEC) has been suggested as a guide to treatment of biofilm infections. We measured an alternative endpoint, the minimum biofilm inhibitory concentration (MBIC) and compared the results with MIC and MBC.
Introduction
Biofilm infections represent a major challenge in current medical practice. Although these infections often occur on medical devices, removal of the device is sometimes unsafe or impractical. Antibiotics can occasionally eradicate biofilm infections, e.g. intravascular catheter-related bloodstream infection (CRBSI), but it is unclear which patients can be treated successfully in this manner. 1, 2 It has been shown that monotherapy with either vancomycin or ampicillin frequently fails to eradicate enterococcal biofilms from patients with CRBSI, when the colonized catheter is left in situ. 2 Failure occurs in spite of apparent susceptibility of the causative organism to such antibiotics in vitro. This suggests that selection of antimicrobial agents for the eradication of microbial biofilms is flawed when based on traditional susceptibility testing methods, such as the broth MIC or breakpoint determination and may result in treatment failure. 3 The aim of this work was to undertake preliminary investigations of an alternative susceptibility testing method that may be more useful in the setting of biofilm infections. We measured a novel variable 'minimum biofilm inhibitory concentration' (MBIC) and compared these values with the MIC and MBC of various antibiotics against enterococcal biofilms. We assessed the impact of additional 
Methods

Bacterial strains
Enterococci from 58 episodes of CRBSI, including 49 Enterococcus faecalis and nine Enterococcus faecium, were studied. 2 (Three isolates from the original 61 consecutive episodes of CRBSI were unavailable.) The 61 episodes of CRBSI, from which the test isolates were derived, were caused by 25 different Strain-types of E. faecalis and 10 different Strain-types of E. faecium. E. faecalis Strain-type A caused 22 of these episodes. E. faecalis NCTC 12697 was used as the control strain.
Antibiotics
Ampicillin, gentamicin and vancomycin were purchased from Sigma Chemical Co. (St Louis, MO, USA). Linezolid powder was a gift from Pharmacia and Upjohn Inc. (Kalamazoo, MI, USA). High-level gentamicin resistance was determined using 200 mg gentamicin discs.
MICs and MBCs
MICs were determined by broth microdilution based on a method published previously. 4 To determine MBC, 5 mL was aspirated from wells where there was no visible growth in the MIC experiment and plated onto horse blood agar (HBA; Oxoid, Basingstoke, UK) plates and incubated overnight at 37 C in air. The MBC was read as the lowest antibiotic concentration to kill 99.9% of the initial inoculum. 5 When antibiotics were tested in combination with gentamicin, it was added at a fixed concentration of 10 mg/L to each antibiotic dilution.
MBIC
Each MBIC experiment was conducted in parallel with MIC and MBC determination. Test isolate, grown on HBA, was inoculated into 10 mL of BHI, then incubated at 37 C, stationary, in air, overnight. Control isolate broth culture (200 mL) was added to each well of one row of a 96 well microtitre plate, leaving column 12 empty. The empty well provided a biofilm-free control peg for each isolate. Test isolate broth culture (200 mL) was added to each well of a row of the microplate. This was repeated for other test organisms using the remaining rows. A polystyrene lid with 96 pins (Transferable solid phase screening system, Nalge Nunc International, Rochester, NY, USA 14602), designed to fit into a 96 well microplate without the pegs touching either the bottom or the sides of the wells, was placed onto the microplate containing the broth cultures and incubated on an orbital shaker (200 rpm) at 37 C in air for 18-20 h. Volumes of antibiotic (200 mL) were added to each well of a second microtitre plate at concentrations in the range 0-8192 mg/L in columns 1-12, respectively. When gentamicin was used, a fixed concentration of 10 mg/L was added to each antibiotic dilution. After overnight incubation, the 96 pin lid was removed from the microtitre plate, shaken gently over a discard pot to remove excess broth and then washed once by immersion of the 96 pin lid in a microtitre plate containing 200 mL of sterile 0.9% (w/v) sodium chloride in each well. The 96 pin lid was then placed onto the microtitre plate containing antibiotics and incubated, stationary, in air for 20 h at 37 C. After incubation, the 96 pin lid was removed from the microtitre plate, shaken gently over a discard pot and washed once by immersion in 0.9% (w/v) sodium chloride. Wells of column 1 of the microtitre plate, which had not contained antibiotic, were examined visually for turbidity as an indication that biofilm had formed on the pegs. The 96 pin lid was then placed onto a microplate containing 200 mL of fresh BHI broth in each well and was incubated overnight, stationary, at 37 C in air. After incubation, the lid was removed and the wells were examined for evidence of turbidity. It was ensured that all wells of column 1, which had contained biofilm pegs without exposure to antibiotics, were turbid and that all wells of column 12, which had contained pegs without biofilm, had no sign of growth. The lowest antibiotic concentration showing no growth after exposure to biofilm was recorded as the MBIC. Assays were repeated at least once and, provided results were within two doubling dilutions of each other, the highest reading was recorded for analysis.
Quantification of biofilm on pegs
To quantify biofilm, the pegs were broken off using a small screwdriver to fracture the polystyrene at the base of the peg. Pegs were transferred into sterile bijou bottles containing 1 mL of sterile saline and sonicated for 15 min. A Whitley automatic spiral plater (Don Whitley Scientific Ltd., Shipley, UK) was used to plate-out and Protocol software (Synbiosis UK, Cambridge, UK) was used to count colony forming units (cfu).
Interpretation of data
Results were expressed in terms of MIC 90 , MBC 90 , MBIC 90 and ranges. Tolerance was defined as a ratio of MBC to MIC ‡32. 6 The effects of antibiotic combinations on MIC, MBC and MBIC of individual isolates were assessed by calculating the ratio of single antibiotic exposure to combination exposure for each isolate. Ratios greater than two, representing more than two doubling dilutions reduction with the combination treatment, and less than 0.25, representing at least two doubling dilutions increase with the combination treatment, were considered 'significant' in this descriptive analysis.
In addition, the sets of MIC data for each species using single antibiotic and combined with gentamicin were collectively compared using the Wilcoxon signed-rank test, using a cut-off P value of 0.05 to reject the null hypothesis, i.e. that there was no significant difference in MICs for the population of isolates tested with and without the addition of gentamicin. Wilcoxon signed-rank test was also used to compare MBCs with and without gentamicin for each antibiotic and MBIC with and without gentamicin for each antibiotic.
Results
The quantities of biofilm that formed on pegs of seven randomly selected isolates are shown in Table 1 . Table 2 summarizes the findings for each antibiotic.
Ampicillin
Tolerance was seen in 48/49 (98%) E. faecalis and 6/9 (66%) E. faecium isolates. Additional gentamicin produced a 'significant' reduction in the MICs obtained for 11 (22%) E. faecalis and 2 (22%) E. faecium isolates. Ampicillin MBCs were reduced by the addition of gentamicin in 27 (55%) E. faecalis isolates and one (11%) E. faecium isolates. Gentamicin caused a 'significant' increase in MBC against five (10%) E. faecalis and two (22%) E. faecium isolates. MBICs of ampicillin were reduced by the addition of gentamicin in 12 (24%) E. faecalis and 3 (33%) E. faecium isolates. High-level susceptibility to gentamicin on disc diffusion testing had a sensitivity of 100% for predicting a significant reduction in MBC with the addition of gentamicin, but specificity (33%) and positive predictive value (58%) were poor. The ability of high-level gentamicin susceptibility to predict synergistic effects on MBIC and MIC was inferior to that for MBC (data not shown).
In the statistical analysis of all E. faecalis isolates, the addition of gentamicin produced a significant reduction in MBC of ampicillin (P = 0.031, Wilcoxon signed-rank test) but did not have a significant impact on MBIC or MIC. In the analysis of all E. faecium isolates there was no statistically significant difference in MIC, MBC or MBIC between exposure to ampicillin alone and in combination with gentamicin (P > 0.05, Wilcoxon signed-rank test).
Linezolid
Tolerance of linezolid was seen in 54/58 (93%) isolates. The addition of gentamicin 'significantly' reduced the MIC of just three (5%) isolates, two E. faecalis and one E. faecium. In contrast, linezolid MBC and MBIC values were 'significantly' reduced by the addition of gentamicin in 57 and 36% of isolates, respectively. When all E. faecalis isolates were analysed collectively, there was a statistically significant reduction in MIC, MBC and MBIC when linezolid was combined with gentamicin (P £ 0.0005, Wilcoxon signed-rank test). The combination only produced a significant reduction in MBIC for E. faecium isolates (P = 0.043, Wilcoxon signed-rank test).
Vancomycin
Vancomycin was tested against 21 E. faecalis and three E. faecium isolates, chosen because this agent was used during therapy for the infections caused by these isolates. All isolates were vancomycin-tolerant with MBCs > 128 mg/L. The addition of gentamicin 'significantly' reduced the MIC for only one isolate but reduced the MBC and MBIC for 50 and 38% of isolates, respectively.
In the analysis of all E. faecalis isolates, the addition of gentamicin produced a significant reduction in both vancomycin MIC and MBIC for E. faecalis (P £ 0.012, Wilcoxon signed-rank test). MBCs were not included in this analysis because they were not quantified above 128 mg/L. Gentamicin had no significant impact on vancomycin MIC or MBIC for E. faecium in this analysis.
Discussion
In vitro susceptibility to ampicillin or vancomycin by routine disc diffusion testing of enterococcal isolates causing intravascular CRBSI was not predictive of treatment success when the catheter was left in situ. 2 We therefore measured the MBIC, a novel endpoint for in vitro susceptibility testing and compared results with standard MIC, MBC and clinical outcome. Equipment equivalent to the Calgary biofilm device was used but we simplified this method, using lack of visible growth in broth culture exposed to pegs as an indicator of biofilm inhibition, rather than quantifying biofilm formed on each peg to shorten the processing time. 7 Peg biofilm load (10 4 -10 5 cfu) was similar to dental biofilm 8 and the organism load used for MIC testing. MBIC 90 of ampicillin, linezolid and vancomycin were 10 3 times greater than MIC 90 , at least twice the MBC 90 , and well above serum levels that are achievable or sustainable in patients.
Ampicillin and vancomycin are often combined with gentamicin for treatment of serious enterococcal infections on the basis of presumed synergy. The addition of gentamicin to linezolid or vancomycin produced a significant reduction in MBC and MBIC The MBIC was above the upper limit of detection (i.e. >8192 mg/L) so no colony count could be performed. n, number of isolates tested.
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